Welcome to our dedicated page for Genenta Science Spa news (Ticker: GNTA), a resource for investors and traders seeking the latest updates and insights on Genenta Science Spa stock.
Genenta Science Spa (GNTA) is a clinical-stage biotechnology pioneer developing gene therapies that reprogram immune cells to target solid tumors. This news hub provides investors and researchers with essential updates on the company's scientific advancements and strategic developments.
Access real-time information on clinical trial progress, regulatory milestones, and partnership announcements. Our curated collection includes press releases covering therapeutic innovations like Temferon for glioblastoma, TEMs-based delivery systems, and hematopoetic stem cell research breakthroughs.
Key updates focus on precision oncology developments, including trial data publications, intellectual property expansions, and collaborative research initiatives. Track the company's progress in creating localized cancer therapies through controlled interferon expression and microrna-mediated gene regulation.
Bookmark this page for streamlined access to verified GNTA updates, financial disclosures, and analysis of their novel immuno-gene therapy platform. Stay informed about developments at the intersection of gene editing and cancer immunotherapy through our maintained news repository.
Genenta Science (NASDAQ: GNTA) has received approval from AIFA for a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), expanding potential applications for its flagship product, Temferon™. This approval aligns with EMA standards. The company's ongoing TEM-GBM development program has completed a Phase 1 dose-ranging trial, confirming no dose-limiting toxicities across 24 patients. Temferon-derived cells remained detectable for over two years post-infusion, with treatment associated with a median survival of 16.8 months and a 25% increase in 2-year overall survival.
The new mRCC trial, targeting high-risk patients with a median overall survival of less than 2 years after multiple therapies, is expected to start in Q4 2024. Recent preclinical studies show synergy between Temferon and other immunotherapies in solid tumors. Genenta will present these developments at upcoming events, including Maxim Group's 2024 Healthcare Virtual Summit and the Society for Neuro-Oncology Annual Meeting.
Genenta Science (NASDAQ: GNTA) recently appointed five new directors to its Board of Directors, including John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider. The company aims to leverage the expertise of these new members to further develop its cell-based platform for treating solid tumors. The shareholders' meeting held on May 2, 2024, marked a significant step towards strengthening the company's leadership and strategic direction.
Genenta Science (NASDAQ: GNTA) announced its fiscal year 2022 financial results, revealing a net loss of €8.5 million, an increase from €5.5 million in 2021. The loss includes a net exchange rate gain of €2.3 million from USD to EUR conversion. The company reported no revenues for 2022, with R&D expenses rising to €5.3 million and G&A expenses at €5.7 million. Genenta holds a €6.4 million tax credit and €29.8 million in cash, estimated to sustain operations into Q1 2025. CEO Pierluigi Paracchi emphasized progress on their lead technology, Temferon, aimed at treating glioblastoma. The annual report is available on the company's investor relations site.
Genenta Science (NASDAQ: GNTA) has announced an amendment to its license agreement with Ospedale San Raffaele (OSR), now allowing access to all solid tumor indications, pending governmental consent. This expansion is expected to enhance Genenta's intellectual property position and treatment options for various cancers. CEO Pierluigi Paracchi highlighted promising preliminary data from the ongoing glioblastoma study, bolstering the decision for broader access. The amended agreement requires approval from the Italian government, which must respond within 90 days for the changes to take effect.
Genenta Science (NASDAQ: GNTA) announced that the FDA has granted Orphan Drug Designation to Temferon™ for glioblastoma multiforme (GBM) treatment. The designation aims to promote the development of Temferon™, a cell therapy targeting tumor microenvironments with immunomodulatory molecules. This decision is expected to enhance Genenta's clinical program addressing the significant unmet medical need in GBM, where about 60% have unmethylated MGMT promoter status. The ODD provides benefits such as federal grants, tax credits for trials, and a seven-year marketing exclusivity post-approval.
FAQ
What is the current stock price of Genenta Science Spa (GNTA)?
What is the market cap of Genenta Science Spa (GNTA)?
